We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti
Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
LONDON & BOSTON--(BUSINESS WIRE)--Keyron appoints former FDA and Boston Scientific leaders as ForePass—a breakthrough device for severe metabolic disease—prepares for clinical trials.
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Boston Scientific (BSX). But which of these two stocks is more attractive to value inve
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
PEMBROKE, Bermuda--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces the secondary listing on the Bermuda Stock Exchange

Boston Sci Q2 Revenue Up 23%

01:30pm, Monday, 28'th Jul 2025
Boston Scientific (BSX -0.17%), a leading medical device maker known for its heart and surgical products, released second-quarter results on July 23, 2025. Revenue reached $5.06 billion for Q2 2025, b

Boston Sci Q2 Revenue Up 23 Percent

02:52pm, Wednesday, 23'rd Jul 2025
Boston Sci Q2 Revenue Up 23 Percent
BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.
Boston Scientific Corporation (NYSE:BSX ) Q2 2025 Earnings Conference Call July 23, 2025 8:00 AM ET Company Participants Jonathan R. Monson - Executive VP & CFO Kenneth M.
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall
Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.62 per share a year ago.
Boston Scientific raised its annual profit forecast on Wednesday, after strong demand for its heart devices helped the U.S. medical device maker beat second-quarter profit estimates.
MARLBOROUGH, Mass. , July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reporte
Boston Scientific (NYSE:BSX) is set to announce its earnings on Wednesday, July 23, 2025. In the last five years, BSX stock has shown a positive return on the day after earnings announcements in 60% o
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE